Lates News

Novo Nordisk announced on March 27th that the U.S. Food and Drug Administration (FDA) has approved Awiqli (insulin icodec-abae, also known by its domestic generic name icodec insulin injection and brand name, Rybelsus injection 700 units/mL. This product is the first and currently the only long-acting basal insulin that can be administered once a week, suitable for adult type 2 diabetes patients to improve their blood sugar control on top of diet and exercise.